The omicron variant of SARS-CoV-2 drove broadly increased seroprevalence in a public university setting.

ABSTRACT: Omicron is the comparatively most transmissible and contagious variant of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). We conducted a seroprevalence study from March 1-3, 2022, to investigate the seroprevalence of SARS-CoV-2 antibodies among individuals aged 18 years and older after the Omicron outbreak. The seroprevalence of anti-receptor binding domain (RBD) antibodies was found to be 96.3% (95% CI 95.2-97.2%) compared to 88.2% (95% CI 86.1-90%) in our previous serosurvey. For anti-nucleocapsid (NC) antibodies, the seroprevalence was 39.1% (95% CI 36.6-41.7%) compared to 19.7% (95% CI 17.5-22.2%) earlier. Individuals that experienced breakthrough infections exhibited the highest levels of anti-RBD antibodies. Additionally, saliva samples showed promise as a potential dia

SUBMITTER: Hou CW 

PROVIDER: S-EPMC11698426 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature